Pediatric dosage forms, methods of making and using
Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the dosage forms, are disclosed.
1. A tablet, consisting of:
a mixture of 25-hydroxyvitamin D 3 , microcrystalline cellulose, starch, magnesium stearate, crospovidone, sucrose, medium chain triglycerides, and silicon dioxide, or
a mixture of 25-hydroxyvitamin D, microcrystalline cellulose, starch, magnesium stearate, crospovidone, sucrose, medium chain triglycerides, silicon dioxide and a disintegrant,
wherein the 25-hydroxyvitamin D 3 is the sole active agent in the tablet.
2. The tablet of claim 1 , wherein the 25-hydroxyvitamin D 3 is present in the tablet in an amount in a range of about 0.01 wt. % to about 0.06 wt. %, based on the total weight of the tablet, based on the total weight of the tablet.
3. The tablet of claim 1 , wherein the 25-hydroxyvitamin D 3 is in an amount in a range of about 1 μg to about 1 g, or about 10 μg to about 100 μg.
4. The tablet of claim 1 , wherein the magnesium stearate is present in the tablet in an amount in a range of about 0.1 wt. % to about 5 wt. %, based on the total weight of the tablet.
5. The tablet of claim 1 , wherein the starch is present in the tablet in an amount in a range of about 70 wt. % to about 90 wt. %, based on the total weight of the tablet.
6. The tablet of claim 1 , wherein the microcrystalline cellulose is present in the tablet in an amount in a range of about 1 wt % to about 30 wt %, based on the total weight of the tablet.
7. A tablet, consisting of a mixture of 25-hydroxyvitamin D 3 and an excipient, the excipient consisting of:
a filler, a disintegrant, a lubricant, and an absorption enhancer, or
a filler, a disintegrant, a lubricant, an absorption enhancer, and a release modifier,
wherein the 25-hydroxyvitamin D 3 is present in the tablet in an amount in a range of about 0.01 wt. % to about 0.06 wt. %, based on the total weight of the tablet, and wherein the filler is present in the tablet in an amount of at least 70 wt %, based on the total weight of the tablet, the lubricant is present in the tablet in an amount in a range of about 0.1 wt. % to about 5 wt. %, based on the total weight of the tablet, and the absorption enhancer is present in the tablet in an amount in a range of about 1 wt. % to about 15 wt. %, based on the total weight of the tablet,
wherein the filler is selected from the group consisting of lactose, saccharose, glucose, starch, microcrystalline cellulose, microfine cellulose, mannitol, sorbitol, calcium hydrogen phosphate, aluminum silicate, amorphous silica, sodium chloride, dibasic calcium phosphate dihydrate, crospovidone, carrageenan, chitosan, pectinic acid, glycerides, beta-cyclodextrine, cellulose derivatives, powdered cellulose, polyplasdone crospovidone, polyethylene oxide, and combinations thereof,
wherein the lubricant is selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, aluminum stearate, talc, siliconized talc, and combinations thereof,
wherein the absorption enhancer is selected from the group consisting of capryolcaproyl macrogolglcyerides, triglycerides, and combinations thereof,
wherein the release modifier is a pore former and is a sugar, and
wherein the 25-hydroxyvitamin D 3 is the sole active agent in the tablet.
8. The tablet of claim 7 , wherein the 25-hydroxyvitamin D 3 is present in the tablet in an amount in a range of about 1 μg to about 1 g, or about 10 μg to about 100 μg.
9. The tablet of claim 7 , wherein the 25-hydroxyvitamin D 3 is present in the tablet in an amount of about 0.03 wt. %.
10. The tablet of claim 7 , wherein the filler is starch.
11. The tablet of claim 7 , wherein the filler is present in the tablet in an amount in a range of about 70 wt. % to about 90 wt. %, based on the total weight of the tablet.
12. The tablet of claim 7 , wherein the filler is crospovidone and microcrystalline cellulose.
13. The tablet of claim 12 , wherein the crospovidone and microcrystalline cellulose are in the tablet in an amount in a range of about 1 wt % to about 30 wt %, based on the total weight of the tablet.
14. The tablet of claim 7 , wherein the lubricant is magnesium stearate.
15. The tablet of claim 7 , wherein the lubricant is in the tablet in an amount in a range of about 0.5 wt. % to about 3 wt. %, based on the total weight of the tablet.
16. The tablet of claim 7 , wherein the sugar is lactose and/or sucrose.
17. The tablet of claim 7 , wherein the caprylocaproyl macrogolglycerides are polyethylene glycosylated glycerides selected from mixtures of monoglycerides, diglycerides, and triglycerides and monoesters, diesters of polyethylene glycol, polyethylene glycosylated almond glycerides, polyethylene glycosylated corn glycerides, or polyethylene glycosylated caprylic/capric triglyceride.
18. The tablet of claim 7 , wherein the absorption enhancer is in the tablet in an amount in a range of about 1 wt. % to about 10 wt. %, based on the total weight of the tablet.
19. The tablet of claim 7 , wherein the absorption enhancer is medium chain triglycerides.
20. The tablet of claim 7 , wherein the mixture is a spray-dried mixture.
21. The tablet of claim 7 , wherein the tablet consists of the 25-hydroxyvitamin D 3 , microcrystalline cellulose, starch, magnesium stearate, crospovidone, sucrose, medium chain triglycerides, and silicon dioxide.
22. A tablet consisting of a spray-dried 25-hydroxyvitamin D 3 composition consisting of a mixture of 25-hydroxyvitamin D 3 , microcrystalline cellulose, starch, magnesium stearate, crospovidone, sucrose, medium chain triglycerides, and silicon dioxide, wherein the 25-hydroxyvitamin D 3 is the sole active agent in the tablet.
23. The tablet of claim 22 , wherein the composition is a compressed tablet.
24. The tablet of claim 22 , wherein the 25-hydroxyvitamin D 3 is present in the tablet in an amount in a range of about 0.01 wt. % to about 0.06 wt. %.
25. A method of treating a vitamin D-responsive disease or condition, a mammal in need of vitamin D supplementation, or a mammal at risk for vitamin D insufficiency or deficiency consisting of administering the tablet according to claim 1 to a mammal in need thereof.
26. The method of claim 25 , wherein the mammal is in need of vitamin D supplementation.
27. The method of claim 25 , wherein the mammal is at risk for vitamin D insufficiency or deficiency.
28. The method of claim 25 , wherein the vitamin D-responsive disease is selected from the group consisting of hyperparathyroidism, hyperparathyroidism secondary to Chronic Kidney Disease (“CKD”), hyperparathyroidism secondary to CKD in mammals undergoing hemodialysis, tertiary hyperparathyroidism, cancer, and autoimmune diseases.
29. The method of claim 28 , wherein the autoimmune disease is selected from the group consisting of type I diabetes, multiple sclerosis, rheumatoid arthritis, polymyositis, dermatomyositis, scleroderma, fibrosis, Grave's disease, Hashimoto's disease, acute or chronic transplant rejection, acute or chronic graft versus host disease, inflammatory bowel disease, Crohn's disease, systemic lupus erythematosis, Sjogren's Syndrome, eczema and psoriasis, dermatitis, and combinations thereof.
30. The method of claim 29 , wherein the dermatitis is selected from the group consisting of atopic dermatitis, contact dermatitis, allergic dermatitis, chronic dermatitis, and combinations thereof.